EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK , ROS1 , or NTRK1 ‐3 Rearrangements

Shengnan Du iD, Zheyi Hu, Jun Shen iD, Lora Hamuro iD, Justine Lam, Ming Lu iD, Li Zhu, Amit Roy, Anna Kondic iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Shengnan Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bristol-Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Models, Biological, Neoplasms, Pyrazoles, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repotrectinib is approved in the US for treating ROS1‐positive non‐small cell lung cancer (NSCLC) and solid tumors harboring an NTRK gene fusion. A Population Pharmacokinetic (PopPK) model for repotrectinib was developed using data from 620 adults (118 healthy volunteers and 502 patients) across seven studies and 24 pediatric patients from one study. The PopPK model, a two‐compartment model with first‐order absorption and an absorption lag time, incorporating a time‐varying clearance due to drug‐induced autoinduction, adequately described all PK data. Clearance was modeled as a time‐ and concentration‐dependent (Ctrough) autoinduction process, accounting for increased clearance over time. While empirical in nature, this Ctrough‐driven autoinduction model effectively described the changes in clearance and avoided the abrupt concentration changes that can occur with discrete dose‐driven autoinduction models. Additionally, this approach avoided time‐consuming differential equation computations for the semi‐mechanistic enzyme turnover autoinduction models. The model estimated that the maximum drug‐induced clearance (CLMAX) was 4.9 times the baseline clearance. Body weight (BW) effects on clearance and volume of distribution were estimated as allometric scaling exponents of 0.477 and 0.962, respectively. Age was found to affect CLMAX, with younger patients generally exhibiting higher CLMAX values. Simulations suggested that a flat dosing regimen (e.g., 160 mg QD for 14 days followed by 160 mg BID) provides comparable drug exposures in both adult and adolescent patients. The PopPK model supported the health authority approval of the dosing regimen for repotrectinib in both adult and adolescent patients with NTRK gene fusion‐positive solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalNeoplasmsPyrazolesAntineoplastic AgentsPyrimidinesHumansAdolescentAdultProtein-Tyrosine KinasesMaleFemaleProto-Oncogene ProteinsReceptor, trkAYoung AdultMiddle AgedAnaplastic Lymphoma KinaseChildAgedDose-Response Relationship, DrugGene RearrangementProtein Kinase InhibitorsOncogene Proteins, FusionCarcinoma, Non-Small-Cell LungLung NeoplasmsReceptor, trkC

Stichwörter der Autor:innen

ALKNTRKROS1advanced solid tumorsautoinductionpediatricsrepotrectinib

Substanzen

ROS1 protein, humanProtein-Tyrosine KinasesProto-Oncogene ProteinsReceptor, trkAAnaplastic Lymphoma KinasePyrazolesALK protein, humanNTRK3 protein, humanNTRK1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Bristol-Myers Squibb, Princeton, New Jersey, USA.
  • Former Employee of BMS, Currently Employed at AbbVie Inc., North Chicago, Illinois, USA.
  • Former Employee of BMS, Currently Employed at Erasca Inc., San Diego, California, USA.
  • Former Employee of BMS, Currently Employed at Avenzo Therapeutics, San Diego, California, USA.
  • Former Employee of BMS, Currently Employed at PumasAI Inc., Dover, Delaware, USA.

ORCID-Profile: Shengnan Du, Jun Shen, Lora Hamuro, Ming Lu, Anna Kondic

Zitieren

APA

Du, S., Hu, Z., Shen, J., Hamuro, L., Lam, J., Lu, M., Zhu, L., Roy, A., & Kondic, A. (2025). A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK , ROS1 , or NTRK1 ‐3 Rearrangements. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70036

Vancouver

Du S, Hu Z, Shen J, Hamuro L, Lam J, Lu M, et al. A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK , ROS1 , or NTRK1 ‐3 Rearrangements. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70036

BibTeX
@article{Du2025,
  author = {Du, Shengnan and Hu, Zheyi and Shen, Jun and Hamuro, Lora and Lam, Justine and Lu, Ming and Zhu, Li and Roy, Amit and Kondic, Anna},
  title = {A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK , ROS1 , or NTRK1 ‐3 Rearrangements},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70036}
}
Kostenlos starten →